Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 1/20 | 0.95 |
| ▸ | LMNA | P02545 | 2/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.60 |
| ▸ | USP2 | O75604 | 1/20 | 0.58 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | PGD | P52209 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9227895 | 1.00 | PDE4A (0.95) | PDE4ALMNATDP1USP2SLCO1B1 | |
| SCHEMBL9228523 | 1.00 | PDE4A (0.95) | PDE4ALMNATDP1USP2SLCO1B1 | |
| SCHEMBL7217913 | 1.00 | PDE4A (0.95) | PDE4ALMNATDP1USP2SLCO1B1 | |
| SCHEMBL9227926 | 1.00 | PDE4A (0.95) | PDE4ALMNATDP1USP2SLCO1B1 | |
| SCHEMBL18585372 | 1.00 | PDE4A (0.95) | PDE4ALMNATDP1USP2SLCO1B1 | |
| SCHEMBL6406 | 1.00 | PDE4A (0.95) | PDE4ALMNATDP1USP2SLCO1B1 | |
| SCHEMBL9227900 | 1.00 | PDE4A (0.95) | PDE4ALMNATDP1USP2SLCO1B1 | |
| SCHEMBL10335266 | 1.00 | PDE4A (0.95) | PDE4ALMNATDP1USP2SLCO1B1 | |
| SCHEMBL21580532 | 1.00 | PDE4A (0.95) | PDE4ALMNATDP1USP2SLCO1B1 | |
| SCHEMBL9232100 | 1.00 | PDE4A (0.95) | PDE4ALMNATDP1USP2SLCO1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115916887-A | Amphiphilic alginic acid particles and method for producing same | 日清纺控股株式会社 | 2023-04-04 | — | — | CN | disclosed |
| CN-115298293-A | Process for preparing solid forms of basic amino acid salts of polyunsaturated fatty acids | 硅循环股份有限公司 | 2022-11-04 | — | — | CN | disclosed |
| US-20220117232-A1 | ANTIMICROBIAL COMPOSITION | BASF SE (DE) | 2022-04-21 | — | — | US | disclosed |
| US-20180243309-A1 | TOPICAL ANTIVIRAL COMPOSITIONS | TOPICAL REMEDY LLC (US) | 2018-08-30 | — | — | US | disclosed |
| EP-3344265-A1 | TOPICAL ANTIVIRAL COMPOSITIONS | Topical Remedy, LLC (US) | 2018-07-11 | — | — | EP | disclosed |
| WO-2017040844-A1 | TOPICAL ANTIVIRAL COMPOSITIONS | TOPICAL REMEDY, LLC (US) | 2017-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220117232-A1 | ANTIMICROBIAL COMPOSITION | CAPG, ST3GAL3, RPN2 | PDE4A 4232/4885LMNA 1336/4885TDP1 2297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.